Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis.
作者信息
Weyer Karin, Falzon Dennis, Jaramillo Ernesto
机构信息
Global Tuberculosis Programme, World Health Organization, 1211 Geneva 27, Switzerland.
出版信息
Bull World Health Organ. 2018 Oct 1;96(10):667-667A. doi: 10.2471/BLT.18.223230.
Abstract
摘要
相似文献
1
Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis.迈向耐药结核病的全口服及更短疗程治疗方案。
Bull World Health Organ. 2018 Oct 1;96(10):667-667A. doi: 10.2471/BLT.18.223230.
2
Now is the time for shorter all-oral regimens for multidrug-resistant tuberculosis.现在是采用更短程全口服方案治疗耐多药结核病的时候了。
Lancet Glob Health. 2019 Jun;7(6):e706. doi: 10.1016/S2214-109X(19)30186-X. Epub 2019 Apr 17.
3
Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.较短疗程耐多药结核病治疗方案的适用标准：世界卫生组织建议中的模糊之处
Am J Respir Crit Care Med. 2016 Oct 15;194(8):1028-1029. doi: 10.1164/rccm.201605-1080LE.
4
Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.欧洲新型较短疗程耐多药结核病治疗方案的获益有限。
Am J Respir Crit Care Med. 2016 Oct 15;194(8):1029-1031. doi: 10.1164/rccm.201606-1097LE.
5
Efficacy and safety of regimens for drug-resistant tuberculosis.耐多药结核病治疗方案的疗效与安全性。
Lancet Infect Dis. 2016 Nov;16(11):1218-1219. doi: 10.1016/S1473-3099(16)30390-5.
6
WHO recommendations on shorter treatment of multidrug-resistant tuberculosis.世界卫生组织关于缩短耐多药结核病治疗疗程的建议。
Lancet. 2016 Jun 18;387(10037):2486-7. doi: 10.1016/S0140-6736(16)30729-2.
7
Revolutionary new treatment regimens for multidrug-resistant tuberculosis.针对耐多药结核病的全新革命性治疗方案。
Lancet Infect Dis. 2019 Mar;19(3):233-234. doi: 10.1016/S1473-3099(19)30060-X.
8
9
World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?世界卫生组织耐多药结核病治疗推荐：是否应采用不同标准？
Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1211-1213. doi: 10.5588/ijtld.17.0199.
10
Multidrug resistant TB: fully oral regimens should help improve compliance, says WHO.世卫组织称，耐多药结核病：全口服治疗方案应有助于提高依从性。
BMJ. 2018 Aug 21;362:k3610. doi: 10.1136/bmj.k3610.
引用本文的文献
1
Oral regimen for multi-drug-resistant TB can promote patient-centred and community-based treatment.耐多药结核病的口服治疗方案可促进以患者为中心和基于社区的治疗。
J Family Med Prim Care. 2021 Dec;10(12):4607-4608. doi: 10.4103/jfmpc.jfmpc_2502_20. Epub 2021 Dec 27.
2
Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review.应对新型抗结核治疗方案经济评估中证据有限导致的不确定性：一项系统综述
Pharmacoecon Open. 2020 Jun;4(2):223-233. doi: 10.1007/s41669-019-0162-z.
3
Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach.儿童耐多药结核病的诊断与管理：实用方法。
Indian J Pediatr. 2019 Aug;86(8):717-724. doi: 10.1007/s12098-018-02846-8. Epub 2019 Jan 17.
本文引用的文献
1
An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.抗多药耐药结核病治疗的更新系统评价和荟萃分析。
Eur Respir J. 2017 Mar 22;49(3). doi: 10.1183/13993003.00803-2016. Print 2017 Mar.
Zotero 插件